Effects of In-Home Addiction Treatment for First Responders

Substance Use Disorders Clinical Trial

Official title:

Effects of an In-Home Treatment Program for First Responders With Substance Use Disorder: A Retrospective Analysis

Clinical Trial Details — Status: Suspended

Administrative data

• NCT number: NCT03907709
• Other study ID #: IHATI-2019-1
• Status: Suspended
• Start date: April 8, 2019
• Est. completion date: July 28, 2020

Study information

• Verified date: August 2019
• Source: In-Home Addiction Treatment Institute, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Retrospective analysis to evaluate impact of an in-home addiction treatment program on first responders with substance use disorder.

Description:

The purpose of this retrospective study is to evaluate the effects of in-home addiction treatment on first responders with substance use disorder. Treatment engagement, hospitalizations, detox and residential addiction treatment admissions, and lethal overdoses will be measured. Although not the primary focus, recidivism and relapse will be measured.

Recruitment information / eligibility

• Status: Suspended
• Enrollment: 15
• Est. completion date: July 28, 2020
• Est. primary completion date: May 28, 2020
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Client is or has been a first responder

• Client enrolled in Aware Recovery Care after April 2017

• Client discharged from Aware Recovery Care before March 2019

• Client has primary substance use disorder diagnosis

Exclusion Criteria:

• Client has never been first responder

• Client moved out of service area or lost insurance during care

Related Conditions & MeSH terms

• Substance Use Disorders
• Substance-Related Disorders

Intervention

Behavioral:
• In-Home Addiction Treatment Program
Treatment was delivered per treatment protocol Primary IHAT Care Team consisted of a licensed Care Coordinator (LPN, RN, MSW, LPC, or LMFT) and two Recovery Advisors Urine drug screens administered randomly Appointments were scheduled per protocol for 52 weeks Within first two weeks of care, all clients are provided an evaluation by a psychiatrist to ensure fitness for program

Locations

Country	Name	City	State
United States	Aware Recovery Care	North Haven	Connecticut

Sponsors (1)

Lead Sponsor	Collaborator
In-Home Addiction Treatment Institute, Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rate of Retention in Treatment	Participation in In-Home Addiction Treatment Program using length of stay reports	Measured throughout 365 day duration of anticipated length of stay
Primary	Brief Addiction Monitor questionnaire	Measure change in client report of symptoms related to substance use disorder	Conducted monthly throughout 365 day anticipated length of stay in program
Primary	Positive Outcomes Measures Survey	Measures changes in quality of life using client self-report inquiring about employment, connection to care team, community engagement using yes/no/not applicable response scale	Completed at week 3 or 4, Week 30, Week 35, Week 44, and Week 50 throughout 52 week anticipated length of program participation
Secondary	Relapse rates	Occurrence of substance use measured through urine drug screening and breathalyzer tests	Randomly administered throughout 365 day anticipated length of program participation
Secondary	Hospitalization	Occurrence of Emergency Room and Inpatient hospital admissions	Measured throughout 365 day anticipated length of program participation
Secondary	Detox and Residential Admissions	Occurrence of residential treatment and detox admission	Measured throughout 365 day anticipated length of program participation